Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity, and emerging clinical trials support this so far. However, some preclinical work and caveats from human studies highlight that more work is needed to understand the mechanisms and full potential of antiobesity medicines in cancer.
Authors
- Donal J. Brennan (ORCID: https://orcid.org/0000-0002-6747-3342)
- Lydia Lynch (ORCID: https://orcid.org/0000-0002-4273-4681)
Institutions
- University College Dublin (IE)
- Princeton University (US)
- Mater Misericordiae University Hospital (IE)
- Institute for Advanced Study (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1158/2159-8290.cd-25-0991
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00